Information is one of the most powerful tools. It is therefore important to have as much information as one can, however, this information must be accurate and reliable. The medical field has so much information but most of it is not freely available to all. However, this is bound to change with the continuous growth and development of Oncotarget. This is an online weekly medical journal founded by Mikhail Blagosklonny and Andrei Gudkov in 2010. The journal aims at making scientific knowledge rapidly and widely known among people and also readily available.
There are many reasons why Oncotarget is preferable among people. First, it is a multidisciplinary journal. It has articles that cover diverse areas of medicine such as cell biology, neuroscience, cardiology, Oncology, pharmacology and endocrinology among others. Additionally, all the papers are reviewed which further enhances their reliability. As such, these papers can be used during medical research and references in reports. The journal is also freely accessible to all. This makes it a convenient source for students most of whom have to pay to access most of the other journal and databases.
The founders of Oncotarget also understand how challenging it can be to have one’s research published. They therefore consider researchers and are willing to edit, peer review and publish their papers for them. It also works with author whose work was accidentally rejected by other journals. Such an author needs to submit the paper that was rejected together with the rebuttal letter and the peer-reviews from the other journal. Through the papers, researchers can share ideas and also have healthy challenges which fuel further research. Oncotarget therefore gives researchers a chance to contribute to the growth of science. It also enables bringing of the gaps between the biomedical sciences by bringing them together. Follow Oncotarget on Twitter.
Mikhail Blagosklonny is a major face at Oncotarget. Besides being a co-founder, Blagosklonny is also an editor-in-chief of Oncotarget. He is also an author with over 250 peer reviewed articles in various journals. He also works with other journals such as the Autography, Cell Cycle, Cell Death Differ and Cancer Res. He is currently a professor at Roswell Park Cancer Institute in Buffalo. Oncotarget, which is published by Impact Journals